Skye Bioscience Inc (SKYE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,474 | 1,835 | 1,858 | 264 | 102 |
| Other current assets | 0 | 8 | 3 | 0 | 7 |
| TOTAL | $2,664 | $1,995 | $1,954 | $556 | $280 |
| Non-Current Assets | |||||
| PPE Net | 7 | 2 | 3 | 1 | 10 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 34 |
| TOTAL | $7 | $2 | $3 | $1 | $44 |
| Total Assets | $2,672 | $1,997 | $1,957 | $557 | $323 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | 235 | N/A |
| Accounts payable and accrued liabilities | 381 | 140 | 16 | 101 | 275 |
| Accrued Expenses | 62 | N/A | N/A | 198 | 266 |
| Other current liabilities | 300 | 831 | 15,923 | 272 | 121 |
| TOTAL | $787 | $971 | $15,939 | $806 | $662 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,434 | 478 | 1,580 | 551 | 1,112 |
| TOTAL | $1,434 | $478 | $1,580 | $551 | $1,112 |
| Total Liabilities | $2,221 | $1,449 | $17,519 | $1,357 | $1,774 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,400 | 733 | 536 | 400 | 103 |
| Common Shares | 288 | 183 | 134 | 34 | 22 |
| Retained earnings | -38,734 | -32,173 | -33,225 | -14,031 | -10,937 |
| Other shareholders' equity | 0 | 0 | 0 | 3,752 | 2,301 |
| TOTAL | $451 | $548 | $-15,562 | $-800 | $-1,451 |
| Total Liabilities And Equity | $2,672 | $1,997 | $1,957 | $557 | $323 |